Voloridge Investment Management
TAK icon

Voloridge Investment Management’s Takeda Pharmaceutical TAK Stock Holding History

Voloridge Investment Management’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-962,502
Closed -$15M – 1278
2025
Q4 		$15M Buy
962,502
+880,289
+1,071% +$12.6M 0.05% 451
2025
Q3 		$1.2M Buy
+82,213
New +$1.22M ﹤0.01% 1015
2025
Q1 		– Sell
-340,953
Closed -$4.51M – 1364
2024
Q4 		$4.51M Buy
340,953
+204,911
+151% +$2.81M 0.02% 804
2024
Q3 		$1.93M Buy
+136,042
New +$1.93M 0.01% 938
2024
Q1 		– Sell
-502,492
Closed -$7.17M – 1351
2023
Q4 		$7.17M Sell
502,492
-70,025
-12% -$994K 0.03% 543
2023
Q3 		$8.86M Sell
572,517
-9,149
-2% -$142K 0.04% 487
2023
Q2 		$9.14M Sell
581,666
-435,102
-43% -$7.13M 0.04% 484
2023
Q1 		$16.8M Sell
1,016,768
-111,604
-10% -$1.78M 0.08% 328
2022
Q4 		$17.6M Buy
1,128,372
+173,345
+18% +$2.42M 0.1% 291
2022
Q3 		$12.4M Sell
955,027
-69,226
-7% -$963K 0.07% 383
2022
Q2 		$14.4M Buy
1,024,253
+706,697
+223% +$10.1M 0.07% 344
2022
Q1 		$4.55M Buy
317,556
+160,304
+102% +$2.35M 0.03% 669
2021
Q4 		$2.14M Buy
+157,252
New +$2.21M 0.01% 1047
2021
Q2 		– Sell
-73,452
Closed -$1.34M – 1782
2021
Q1 		$1.34M Buy
73,452
+20,591
+39% +$370K 0.01% 941
2020
Q4 		$962K Sell
52,861
-73,695
-58% -$1.29M 0.01% 978
2020
Q3 		$2.26M Buy
126,556
+50,838
+67% +$926K 0.02% 678
2020
Q2 		$1.36M Sell
75,718
-1,854
-2% -$33.3K 0.02% 746
2020
Q1 		$1.18M Sell
77,572
-290,044
-79% -$5.26M 0.03% 470
2019
Q4 		$7.25M Buy
367,616
+183,443
+100% +$3.51M 0.14% 184
2019
Q3 		$3.17M Buy
184,173
+162,428
+747% +$2.81M 0.06% 344
2019
Q2 		$385K Buy
+21,745
New +$396K 0.01% 610

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Voloridge Investment Management's TAK Position: Q1 2026 in Review

Voloridge Investment Management sold out of Takeda Pharmaceutical (TAK) in Q1 2026, closing a stake of 962,502 shares — an estimated $15M sold.

Voloridge Investment Management first reported a position in TAK in Q2 2019 and held it in 21 quarters. The position peaked at $17.6M in Q4 2022. 361 funds tracked by Wall St. Rank hold TAK as of Q1 2026.

  • Voloridge Investment Management reported no remaining Takeda Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • Voloridge Investment Management sold 962,502 Takeda Pharmaceutical shares in Q1 2026, an estimated $15M.
  • Voloridge Investment Management first reported a position in Takeda Pharmaceutical in Q2 2019 and held it in 21 quarters.
  • Voloridge Investment Management's Takeda Pharmaceutical position peaked at $17.6M in Q4 2022.
  • 361 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2026.

Based on Voloridge Investment Management's 13F filing for Q1 2026, filed 15 May 2026.